XEN1101 for Major Depressive Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Epistemonikos ID: 1bcdef4c85dcbbe1299259b6cd3c871aa8509207
First added on: May 08, 2024